Enzymes: Still cool after all these years
The first enzyme was discovered in 1833, almost 200 years ago and long before the nature of proteins was appreciated. The field of enzymology came into its own in the 20th century. Technological advances in the hands of creative enzymologists led to an ever-growing understanding of how enzymes achieve enormous rate accelerations as well as the structural basis for substrate specificity and allosteric regulation.
Submit an abstract
Abstract submission begins Sept. 14. If you submit by Oct. 12, you'll get a decision by Nov. 1. The regular submission deadline is Nov. 30. See the categories.
Enzymologists continue to break new ground as we enter the 21st century. Our session at Discover BMB will feature new work on enzyme functions, mechanisms and applications.
Our first group of speakers will focus on enzymes that deal with problems caused by misbehaving metabolites. They will describe how enzymes can protect unstable intermediates and repair damaged metabolites. Our second group will explore the potential of using enzymes for biodegradation and green biosynthesis of chemicals currently produced from petrochemicals. Our final group will focus on enzymes that catalyze novel reactions, pushing the boundaries of chemistry accessible through biocatalysts.
Keywords: Substrate channeling, metabolite repair, biodegradation, green chemistry, natural product biosynthesis, radical chemistry.
Who should attend: Anyone who appreciates the awesome power of enzyme catalysis.
Theme song: “Still Crazy After All These Years” by Paul Simon, because enzymes are crazy-efficient catalysts
This session is powered by the ribosome, which produces the enzymes that make life possible.
Cool and novel enzymes
Enzymatic control of problematic intermediates
Chair: Hung-Wen (Ben) Liu

Shelley D. Copley, University of Colorado Boulder
Tom Niehaus, University of Minnesota, Twin Cities
Shelley Minteer, University of Utah
Carole Linster, University of Luxembourg
Enzymes for a sustainable future
Chair: Shelley D. Copley
Gregg Beckham, National Renewable Energy Laboratory
Larry Wackett, University of Minnesota
Michelle Chang, University of California, Berkeley
Raquel Lieberman, Georgia Institute of Technology
New and unusual enzymatic transformations
Chair: Michelle Chang
Hung-wen (Ben) Liu, University of Texas at Austin
Aimin Liu, University of Texas at San Antonio
Sara O'Connor, Max Planck Institute for Chemical Ecology
Wenjun Zhang, University of California, Berkeley
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Mass spec method captures proteins in native membranes
Yale scientists developed a mass spec protocol that keeps proteins in their native environment, detects intact protein complexes and tracks drug binding, offering a clearer view of membrane biology.

Laser-assisted cryoEM method preserves protein structure
University of Wisconsin–Madison researchers devised a method that prevents protein compaction during cryoEM prep, restoring natural structure for mass spec studies. The approach could expand high-resolution imaging to more complex protein systems.

Method sharpens proteome-wide view of structural changes
Researchers developed a method that improves limited proteolysis coupled with mass spectrometry, separating true changes from abundance or splicing effects.

Discoveries made possible by DNA
The discovery of DNA’s double helix revealed how genetic information is stored, copied and expressed. Revisit that breakthrough and traces how it laid the foundation for modern molecular biology, genomics and biotechnology.

Unraveling the language of histones
Philip Cole presented his research on how posttranslational modifications to histones are involved in gene expression and how these modifications could be therapeutically targeted to treat diseases like cancer.

How Alixorexton could transform narcolepsy treatment
A new investigational drug, alixorexton, targets the brain’s orexin system to restore wakefulness in people with narcolepsy type 1. Alkermes chemist Brian Raymer shares how molecular modeling turned a lab idea into a promising phase 3 therapy.